Alkermes PLC (ALKS)

56.25
NASDAQ : Health Care
Prev Close 54.89
Day Low/High 54.37 / 56.73
52 Wk Low/High 27.14 / 80.71
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 151.97M
Market Cap 8.34B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alkermes' Corporate Presentation To Be Webcast At The Jefferies 2016 London Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The Jefferies 2016 London Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2016 London Healthcare Conference on Wednesday, Nov.

ALKERMES Inspiration Grants™ Awarded To Support People Affected By Mental Health And Substance Use Disorders

ALKERMES Inspiration Grants™ Awarded To Support People Affected By Mental Health And Substance Use Disorders

Alkermes plc (NASDAQ: ALKS), a global biopharmaceutical company developing medicines for the treatment of central nervous system (CNS) diseases, today announced the company has awarded $1 million in funds to...

Alkermes Plc Reports Third Quarter 2016 Financial Results

Alkermes Plc Reports Third Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) today reported financial results for the third quarter of 2016.

Alkermes' Corporate Presentation To Be Webcast At The Credit Suisse 25th Annual Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The Credit Suisse 25th Annual Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 25 th Annual Healthcare Conference on Tuesday, Nov.

Jim Cramer's Top Takeaways: Norfolk Southern, Apple, Snap-On

Jim Cramer's Top Takeaways: Norfolk Southern, Apple, Snap-On

Jim Cramer sees the possibility of growth for Norfolk Southern and Snap-On.

Jim Cramer's 'Mad Money' Recap: Demand and Takeover Talk Lift Stocks

Jim Cramer's 'Mad Money' Recap: Demand and Takeover Talk Lift Stocks

Strong demand drives results and gains for Boeing, Akamai and others.

Alkermes To Host Conference Call To Discuss Third Quarter 2016 Financial Results

Alkermes To Host Conference Call To Discuss Third Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Materials, financials, cyclicals and health care names tilt the scale to the bullish side.

A Democratic Sweep?; M&A Just the Beginning: Jim Cramer's Best Blogs

A Democratic Sweep?; M&A Just the Beginning: Jim Cramer's Best Blogs

Jim Cramer ponders why M&A is just the start of the story and also wonders what a Democratic sweep would do to the markets.

Jim Cramer's 'Mad Money' Recap: Takeover Talk Distracts From Earnings Focus

Jim Cramer's 'Mad Money' Recap: Takeover Talk Distracts From Earnings Focus

M&A may dominate headlines, but investors need to watch earnings as well, says Jim Cramer.

Alkermes (ALKS) Stock Soars on Trial Results, Upgrades

Alkermes (ALKS) Stock Soars on Trial Results, Upgrades

Alkermes (ALKS) said that its depression drug showed positive results in a late-stage clinical trial, prompting analysts to raise their ratings on the stock.

Cramer: M&A Is Just the Beginning of Today's Story

Cramer: M&A Is Just the Beginning of Today's Story

Ask not for whom the register rings, and it better not ring for thee.

Analysts' Actions -- Alkermes, Chesapeake, Microsoft, Yahoo! and More

Analysts' Actions -- Alkermes, Chesapeake, Microsoft, Yahoo! and More

Here are Friday's top research calls, including upgrades for Alkermes, Chesapeake Energy and Microsoft, and a downgrade for Yahoo!.

Alkermes Depression Drug Finds Success on Third Study Attempt

Alkermes Depression Drug Finds Success on Third Study Attempt

Third time was the charm for Alkermes' experimental antidepressant ALKS 5461.

Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study Of ALKS 5461 For Major Depressive Disorder

Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study Of ALKS 5461 For Major Depressive Disorder

Alkermes plc (NASDAQ: ALKS) today announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational...

Alkermes Announces Initiation Of Clinical Study Evaluating Metabolic Profile Of ALKS 3831 For Treatment Of Schizophrenia

Alkermes Announces Initiation Of Clinical Study Evaluating Metabolic Profile Of ALKS 3831 For Treatment Of Schizophrenia

Alkermes plc (NASDAQ: ALKS) today announced the initiation of a clinical study designed to evaluate the metabolic profile of ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate, compared...

Jim Cramer -- Gilead Needs to Make an Acquisition

Jim Cramer -- Gilead Needs to Make an Acquisition

Investors shouldn't give up on Gilead's Hep. C drug, Cramer says.

Alkermes Announces Webcast Of Analyst And Investor Event On September 26, 2016

Alkermes Announces Webcast Of Analyst And Investor Event On September 26, 2016

Alkermes plc (NASDAQ: ALKS) announced today that it will webcast its Analyst and Investor Event presentation on Monday, September 26, 2016.

ALKERMES™ Inspiration Grants Application

ALKERMES™ Inspiration Grants Application

Alkermes plc (NASDAQ: ALKS), a global biopharmaceutical company developing medicines for the treatment of central nervous system (CNS) diseases, such as schizophrenia, major depressive disorder and multiple sclerosis,...

Alkermes' Corporate Presentation To Be Webcast At The Morgan Stanley Global Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The Morgan Stanley Global Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Morgan Stanley Global Healthcare Conference on Monday, Sept.

Want a Dash for Trash? Why Not Look at Alkermes

Want a Dash for Trash? Why Not Look at Alkermes

Sometimes, buying low can work as a balance, almost a strange sort of diversification.

Alkermes Submits Supplemental New Drug Application To FDA For Two-Month Dosing Option Of ARISTADA® For Treatment Of Schizophrenia

Alkermes Submits Supplemental New Drug Application To FDA For Two-Month Dosing Option Of ARISTADA® For Treatment Of Schizophrenia

Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.

Alkermes (ALKS) Is Today's Dead Cat Bounce Stock

Alkermes (ALKS) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Alkermes (ALKS) as a "dead cat bounce" (down big yesterday but up big today) candidate

Water-Logged And Getting Wetter: Alkermes (ALKS)

Water-Logged And Getting Wetter: Alkermes (ALKS)

Trade-Ideas LLC identified Alkermes (ALKS) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Alkermes Plc Reports Second Quarter 2016 Financial Results

Alkermes Plc Reports Second Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) today reported financial results for the second quarter of 2016.

Jim Cramer's Top Takeaways: Acacia Communications, KeyCorp, Alkermes

Jim Cramer's Top Takeaways: Acacia Communications, KeyCorp, Alkermes

Cramer says to be careful with Acacia Communications but he's a big fan of KeyCorp.

Jim Cramer's 'Mad Money' Recap: 'Good Enough' Is a Triumph

Jim Cramer's 'Mad Money' Recap: 'Good Enough' Is a Triumph

There were many earnings reports today, and many could've been worse, Cramer says.

Alkermes To Host Conference Call To Discuss Second Quarter 2016 Financial Results

Alkermes To Host Conference Call To Discuss Second Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.